Clinical Laserthermia Systems

Lund, SwedenFounded 200611–50 employeesclinicallaser.seLinkedIn

Clinical Laserthermia Systems AB (CLS) is a Lund, Sweden-based medical technology company developing and manufacturing minimally invasive laser ablation systems for precise treatment of diseased tissue. Its products primarily support focal therapy for localized prostate cancer and laser interstitial thermal therapy in neurosurgery, with image guidance and real-time temperature monitoring.

Visit clinicallaser.se ↗

Founded: 2006
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

Recent highlights

Clinical Laserthermia Systems entered a more active financing and commercialization phase during 2025 and 2026. On Dec 3, 2025, it submitted a CE-marking application for the ClearPoint Prism Neuro Laser Therapy System, supporting expansion into European neurosurgery. On Jan 8, 2026, the TRANBERG Thermal Therapy System was installed at Andros Clinics in Amsterdam for an ultrasound-guided focal laser ablation program for localized prostate cancer, in collaboration with MTEC Company and Andros Clinics. The company also strengthened its strategic relationship with an unnamed partner on Apr 28, 2026, with commitments through 2030 covering ClearPoint Prism system placements, regulatory expansion, and next-generation product development. Financing activity accelerated in August and September 2026, including a SEK 31 million post-IPO equity round on Aug 20, 2026 and a further SEK 1.97 million round on Sep 3, 2026. Governance and management also changed: Katarina Lundqvist became permanent CFO on Sep 1, 2026, while the company disclosed a roughly EUR 600,000 repayment obligation related to a historical Horizon 2020 grant.

Market position

Clinical Laserthermia Systems operates at the intersection of surgical robotics-adjacent medical devices, laser ablation, oncology, and neurosurgery. Its principal differentiation is an integrated platform that combines 1064 nm laser hardware, procedure-specific applicators and introducers, temperature probes, thermometry software, and image-guided workflows. TRANBERG targets focal treatment of soft-tissue lesions, including localized prostate cancer, while Prism extends the platform into laser interstitial thermal therapy for brain lesions and epileptogenic foci. ClearPoint Neuro is a significant commercial partner and channel relationship rather than a direct peer, helping distribute the Prism-branded system in MRI-guided neurosurgery. CLS nevertheless has a narrower, procedure-focused profile than diversified device groups, with commercialization concentrated in urology and neurosurgery. Its ISO certification under the Medical Device Regulation in 2024 and CE-marking application for Prism indicate regulatory progress, but the company remains a small, public medtech business with approximately 13 employees and limited disclosed investor breadth.

Growth & opportunities

CLS shows a financing-led growth trajectory with increasing emphasis on commercialization and neuro-focused applications. The company raised SEK 114.2 million through a rights issue in 2023 and completed a SEK 22.4 million directed issue in November 2024. It then recorded post-IPO equity activity of approximately SEK 20.9 million on Sep 30, 2025, SEK 31 million on Aug 20, 2026, and SEK 1.97 million on Sep 3, 2026. Operationally, the January 2026 installation at Andros Clinics created a pathway for ultrasound-guided prostate cancer procedures, while the April 2026 strategic alignment through 2030 targeted broader ClearPoint Prism placements and regulatory expansion. The 2024 MDR-related ISO certification and 2025 Prism CE-marking submission represent important regulatory inflection points. Management has also been reshaped through the appointment of a permanent CFO in September 2026 and earlier additions to operations and medical affairs. Growth remains capital dependent: the company reports approximately 13 employees, and a roughly EUR 600,000 grant repayment obligation disclosed in 2026 may constrain near-term resources.

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

What makes Clinical Laserthermia Systems distinct

reccy insights

What makes Clinical Laserthermia Systems distinct

01Patented laser ablation technology designed to precisely destroy targeted tissue while preserving surrounding healthy tissue.
02Integrated product platform combining laser systems, sterile applicators, introducers, temperature probes, and thermometry software.
03Integration with MRI and ultrasound-fusion imaging and navigation platforms for image-guided procedures.
04Commercial focus on minimally invasive treatments in urology and neurosurgery, including localized prostate cancer and brain lesions.
05Strategic commercialization partnerships supporting market access in the United States and Europe.

Technology & products4

Technology & products

TRANBERG® Thermal Therapy System
An image-guided laser ablation system for controlled thermal treatment of soft-tissue lesions, including focal treatment of localized prostate cancer and other oncology applications.
Prism® Neuro Laser Therapy System
A neurosurgical laser therapy system powered by CLS technology for laser interstitial thermal therapy of brain lesions and epileptogenic foci under image guidance.
CLS Mobile Service Provider (MSP) Model
A procedure-based service that supplies the TRANBERG® system, accessories, disposables, and on-site clinical and technical support for a fixed fee per patient.
imILT® Interstitial Laser Thermotherapy
An interstitial laser thermotherapy approach that uses controlled heating to ablate tumor tissue and potentially stimulate an immune response against cancer cells.

Show all 4 products

+ 1 more: imILT® Interstitial Laser Thermotherapy

Recent updates15

Launches, partnerships and team changes from press coverage

Sep 1, 2026Team change
Clinical Laserthermia Systems appointed Katarina Lundqvist permanent CFO after her interim consultancy role, providing management continuity.
news.cision.com
Apr 28, 2026Partnership
Clinical Laserthermia Systems and an unnamed strategic partner agreed on a new alignment through 2030 to accelerate growth of the ClearPoint Prism neuro laser therapy business, including stronger commercial commitments, coordinated system placements, regulatory expansion, and joint next-generation product development.
news.cision.com
Jan 8, 2026Product launch
Clinical Laserthermia Systems has deployed its TRANBERG Thermal Therapy System at Andros Clinics in Amsterdam to enable a new ultrasound-guided focal laser ablation treatment program for localized prostate cancer.
news.cision.com
Jan 8, 2026Partnership
Clinical Laserthermia Systems, MTEC Company, and Andros Clinics are collaborating to launch an ultrasound-guided focal laser ablation program for localized prostate cancer in the Netherlands using the TRANBERG Thermal Therapy System.
news.cision.com
Dec 3, 2025Partnership
Clinical Laserthermia Systems continued its global commercialization partnership with ClearPoint Neuro for the ClearPoint Prism Neuro Laser Therapy System used in MRI-guided neurosurgery.
news.cision.com
Jun 27, 2025Team change
Shareholders elected four new directors to strengthen governance and expertise in neuro and supply chain.
news.cision.com
Jun 27, 2025Team change
Peter Max was re-elected as Chairman of the Board, and Lena Höglund, Veronica Byfield, Thomas Binzer, and Jerker Nygren were elected as Board members.
news.cision.com
Feb 7, 2025Team change
Lars-Erik Eriksson, co-founder and former CEO, left the board of directors at his own request.
news.cision.com
Jan 14, 2025Partnership
CLS Recaps 2024 and Provides Outlook for 2025-26
tradingview.com
Sep 30, 2024Team change
Hans von Celsing announced his intention to step down from the Board of Directors after serving as Chairman for more than ten years.
news.cision.com
Mar 22, 2024Team change
Clinical Laserthermia Systems appointed Håkan Rosqvist as interim CFO.
news.cision.com
Dec 19, 2023Team change
Clinical Laserthermia Systems appointed Kristian Waldeck as VP Medical Affairs and a member of the management team.
news.cision.com
Sep 8, 2023Team change
Rolf Ho Bornschein resigned as CFO.
marketscreener.com
May 22, 2023Team change
Clinical Laserthermia Systems expanded its management team by appointing an Executive Vice President Operations.
news.cision.com
Aug 12, 2022Team change
Clinical Laserthermia Systems appointed a new CFO.
news.cision.com

Show all 15 updates

About Clinical Laserthermia Systems

Products: TRANBERG® Thermal Therapy System, Prism® Neuro Laser Therapy System, CLS Mobile Service Provider (MSP) Model, imILT® Interstitial Laser Thermotherapy
Leadership: Katarina Lundqvist, CFOStefan Astrom, Vice President Clinical OperationsRolf Ho Bornschein, CFO
Focus areas: Medical devices, medtech, laser ablation, minimally invasive surgery, oncology, neurosurgery, urology, prostate cancer
Headquarters: Lund, Sweden
Founded: 2006
Employees: 11–50
Patents granted: 14 (Crunchbase)
Trademarks: 11